Previous 10 | Next 10 |
Significant single-agent activity in diffuse large B-cell lymphoma (DLBCL) cell models and in mouse model showed superiority to lenalidomide (Revlimid ® ) Synergistic activity with rituximab in DLBCL mouse model resulted in complete regressions and was superior to the approved ...
HOUSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) , a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, will hold a conference call with sl...
60% Confirmed Disease Control Rate 1 and 7.4 Months Median Time to Tumor Progression for Ewing Sarcoma First-Relapse Patients No Disease Progression Observed in Either First- or Second-Relapse Ewing Sarcoma Patients Who Achieved Confirmed Disease Control HOUSTON, Dec. ...
Salarius Pharmaceuticals press release ( NASDAQ: SLRX ): Q3 GAAP EPS of -$6.41, which included a loss on goodwill impairment of $8.9 million, or an impairment of $3.94 per share. Cash and cash equivalents were $16.8 million as of September 30, 2022, compared with $29.2 mil...
HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) , a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financ...
HOUSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) , a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that two abst...
Data showcased novel compound with potential for improved anti-cancer activity over other molecular glues Salarius plans to release additional preclinical results at the American Society of Hematology annual meeting later this year HOUSTON, Oct. 27, 2022 (GLOBE NEW...
HOUSTON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) , a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that Daniela ...
Clinical-stage biotech Salarius Pharmaceuticals, Inc. ( NASDAQ: SLRX ) shed ~27% at the open Tuesday after the company said that following a death of the study subject it will pause enrollment of new patients in the Phase 1/2 trial for lead asset seclidemstat in connective...
HOUSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) , a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that, as per ...
News, Short Squeeze, Breakout and More Instantly...
Salarius Pharmaceuticals Inc. Company Name:
SLRX Stock Symbol:
NYSE Market:
Salarius Pharmaceuticals Inc. Website:
2024-06-17 09:02:04 ET Solar Acquisition Corp (SLRX) announced stock split at a ratio of 1-for-8 on 2024-06-17 ... Full story available on KlickAnalytics.com
Patients were treated in the dose-escalation portion of the Phase 1/2 study evaluating seclidemstat in combination with azacitidine Investigators reported a 43% overall response rate among 14 predominantly higher risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (C...
HOUSTON, June 12, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) , a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that it will effect...